Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -34.24% is 23% above its 5-year average of -44.53%, around the middle of its 5-year range (-66.92%–-17.52%).
34.23% above its 12-month average of -52.06%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.15%.
RETURN ON ASSETS (ROA)
-34.24%
RETURN ON ASSETS (ROA) AVG TTM
-52.06%
RETURN ON ASSETS (ROA) AVG 3Y
-53.17%
RETURN ON ASSETS (ROA) AVG 5Y
-44.53%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+34.23%
CURRENT VS 3Y AVG
+35.60%
CURRENT VS 5Y AVG
+23.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-6.20%
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$256.77M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$256.68M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$257.37M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$258.73M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$258.85M
Return on Assets (ROA)
-35.62%
TTM Avg
-26.42%
3Y Avg
-45.47%
5Y Avg
-51.35%
Market Cap
$262.00M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$261.24M
Return on Assets (ROA)
-25.09%
TTM Avg
-72.59%
3Y Avg
-80.80%
5Y Avg
-146.30%
Market Cap
$261.28M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$251.10M
Return on Assets (ROA)
-55.66%
TTM Avg
-26.79%
3Y Avg
-50.07%
5Y Avg
-50.07%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $256.77M | -34.24% | -52.06% | -53.17% | -44.53% |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.68M | -2.06% | -16.77% | -17.09% | -12.28% |
| AC Immune S.A. (ACIU)vs › | $257.37M | -29.15% | -33.84% | -33.85% | -31.54% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $258.73M | -35.96% | -58.88% | -82.10% | -113.46% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $258.85M | -35.62% | -26.42% | -45.47% | -51.35% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | -134.38% | -47.50% | -42.91% | -40.55% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -25.09% | -72.59% | -80.80% | -146.30% |
| OraSure Technologies, Inc. (OSUR)vs › | $261.28M | -13.63% | -10.56% | -3.47% | -3.69% |
| Upstream Bio, Inc. (UPB)vs › | $251.10M | -55.66% | -26.79% | -50.07% | -50.07% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
ROA
-34.2%
ROE
-37.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.20% |
| 2024-12-31 | -66.92% |
| 2023-12-31 | -47.49% |
| 2022-12-31 | -61.06% |
| 2021-12-31 | -36.99% |
| 2020-12-31 | -17.52% |
